OTCMKTS:CYBN Cybin (CYBN) Stock Price, News & Analysis $7.47 +0.21 (+2.89%) As of 05/23/2025 04:10 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsHeadlinesSEC FilingsBuy This Stock About Cybin Stock (OTCMKTS:CYBN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Cybin alerts:Sign Up Key Stats Today's Range$7.00▼$7.5050-Day Range$5.00▼$7.7052-Week Range$4.81▼$13.88Volume226,170 shsAverage Volume276,250 shsMarket Capitalization$160.43 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewCybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation. It has also developed EMBARK, a psychological support model that integrates clinical approaches to promote supportive healing with psychedelic medicine. The company is headquartered in Toronto, Canada.Read More… Receive CYBN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cybin and its competitors with MarketBeat's FREE daily newsletter. Email Address CYBN Stock News HeadlinesCybin CEO to Speak at Healthcare Showcase, Highlighting Innovations in Mental Health TreatmentMay 14, 2025 | tipranks.comCybin to Participate in the Alliance Global Partners Healthcare Company ShowcaseMay 14, 2025 | financialpost.comTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.May 24, 2025 | Porter & Company (Ad)Cybin to Participate in the Alliance Global Partners Healthcare Company ShowcaseMay 14, 2025 | financialpost.comCybin (OTCMKTS:CYBN) Shares Down 0.5% - Here's What HappenedMay 14, 2025 | americanbankingnews.comCybin to Participate at the 28th Annual Milken Institute Global ConferenceMay 1, 2025 | theglobeandmail.comGuggenheim Initiates Coverage of Cybin (CYBN) with Buy RecommendationMarch 14, 2025 | msn.comCybin Inc. (CYBN): Among the Best Psychedelic Stocks to Buy in 2025March 1, 2025 | insidermonkey.comSee More Headlines CYBN Stock Analysis - Frequently Asked Questions How have CYBN shares performed this year? Cybin's stock was trading at $8.82 at the beginning of the year. Since then, CYBN stock has decreased by 15.3% and is now trading at $7.47. View the best growth stocks for 2025 here. How do I buy shares of Cybin? Shares of CYBN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cybin own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cybin investors own include NVIDIA (NVDA), Meta Platforms (META), Pfizer (PFE), Advanced Micro Devices (AMD), Broadcom (AVGO), CrowdStrike (CRWD) and Company Calendar Today5/24/2025Fiscal Year End3/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:CYBN CIK1833141 Webwww.cybin.com Phone(866) 292-4601FaxN/AEmployees50Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($4.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,930,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-93.17% Return on Assets-84.68% Debt Debt-to-Equity RatioN/A Current Ratio2.61 Quick Ratio2.61 Sales & Book Value Annual Sales$680,000.00 Price / Sales235.93 Cash FlowN/A Price / Cash FlowN/A Book Value$0.19 per share Price / Book39.32Miscellaneous Outstanding Shares21,477,000Free Float170,213,000Market Cap$160.43 million OptionableNot Optionable Beta0.60 Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (OTCMKTS:CYBN) was last updated on 5/24/2025 by MarketBeat.com Staff From Our PartnersMarket chaos is the new normalIt happened again. Wall Street swung like a wrecking ball after Trump paused tariffs on smartphones, lapto...Augusta Precious Metals | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | Sponsored$19 for a FULL YEAR of stock picks?!Invest in Musk's AI Play With Just $100 You don't need deep pockets to ride the next wave of AI wealth. ...Behind the Markets | SponsoredTrump Quietly Planning $15 Trillion Crypto ShockerMost investors are still unaware, but I believe a new White House action may have quietly opened the floodgate...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredAfter Monday, price goes up 600% (hurry)Right now, for a limited time… You can get up to 52 Money Monday trades for just $7! Thanks to Wall Street’...Timothy Sykes | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cybin Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cybin With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.